| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
22046 |
| Drug |
Nivolumab |
| Brand |
Opdivo® |
| Indication |
Is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC. |
| Rapid review commissioned |
01/07/2022 |
| Rapid review completed |
08/08/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab for this indication compared with the current standard of care |
| Full pharmacoeconomic assessment commissioned by HSE |
31/08/2022 |
| Pre-submission consultation with Applicant |
29/11/2022 |
| Full submission received from Applicant |
21/02/2023 |
